1. Scrip
  2. >>New Products

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: the outlook for 2025 launches; Merck confident in new pneumococcal vaccine; multiple US setbacks for Japanese firms; Stock Watch on Moderna missteps; and Sun’s North America head talks plans and strategy.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 21 June 2024, including: the outlook for 2025 launches; Merck & Co., Inc. confident in new pneumococcal vaccine; multiple US setbacks for Japanese firms; Stock Watch on Moderna, Inc. missteps; and Sun Pharmaceutical Industries Ltd.’s North America head talks plans and strategy. 

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "Cagrisema Leads The Charge For 2025" - Scrip, 19 June, 2024.)

(Also see "Merck’s Newly Approved Capvaxive Could Have Edge Over Prevnar 20 In Adults" - Scrip, 18 June, 2024.)

(Also see "US R&D Setbacks For Multiple Japanese Firms" - Scrip, 14 June, 2024.)

(Also see "Stock Watch: Thoroughly Moderna Missteps" - Scrip, 18 June, 2024.)

(Also see "Sun’s Gandhi On US Specialty Journey Sans ‘Baggage’, Deuruxolitinib" - Scrip, 17 June, 2024.)

Citeline · Scrip's Five Must-Know Things - 24 June 2024

Open Media

More from New Products

Stealth Bio Bags Elamipretide FDA Win After Multiple Setbacks

 
• By Sushmita Panda

Stealth won FDA accelerated approval for Forzinity, the first Barth syndrome therapy, after multiple regulatory setbacks. The decision sets the stage for confirmatory trials and expanded patient access.

Pipeline Watch: Six Approvals And Twenty Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Sanofi’s Pipeline Pressure Continues As Tolebrutinib Trips Near Finish Line

 
• By Manas Mishra

Sanofi’s MS hopeful tolebrutinib hits a regulatory hurdle in the US, renewing pressure on the firm’s pipeline. Analysts hope the delay won’t prove material.

Merck Scores US FDA Approval For Subcutaneous Keytruda Qlex

 
• By Alaric DeArment

The agency approved the subcutaneous formulation of the PD-1 inhibitor, months after approving a subcutaneous version of BMS’s Opdivo.

More from Scrip

EADV: UCB’s Bimzelx Primed To Maintain Pole Position in HS

 
• By Kevin Grogan

The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 
• By Alexandra Shimmings

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

Pipeline Watch: Six Approvals And Twenty Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.